Gustavo Doncel

Gustavo Doncel, M.D., Ph.D.


As part of the 30 year-long CONRAD program, Dr. Doncel is the Scientific and Executive Director and Principal Investigator.  Dr. Doncel works on reproductive health, contraception, mucosal immunology, HIV-1 prevention, microbicide development, and the unique aspects of microbicide interactions with the cervicovaginal (CV) mucosa. With NIH and USAID funding, Dr. Doncel began working on HIV microbicides in 1990. As a key member of CONRAD leadership, he directs multi-project, multi-institutional R&D efforts, especially on anti-HIV and contraceptive product development.  He has served or is currently serving as an advisor to the International Partnership for Microbicides, NIH/NIAID (as reviewer and member of working groups), European Commission Research Directorate General, European microbicides development consortia (EMPRO and CHAARM), and the World Health Organization. He has published extensively on microbicide development, contraceptive and infertility research and mucosal safety. Dr. Doncel received his M.D and Ph.D. from the University of Buenos Aires, Argentina, and performed his Postdoctoral work in Reproductive Immunology from the Eastern Virginia Medical School.


Meredith Clark

Meredith Clark, Ph.D

Director, Preclinical Activities / Assoc Professor of Obstetrics and Gynecology

Dr. Clark is the Director of Preclinical Activities at CONRAD and Associate Professor of Obstetrics and Gynecology at Eastern Virginia Medical School. She is responsible for the preclinical research and development of drug products and other biomedical technologies in CONRAD’s pipeline. With over 9 years of experience at CONRAD, she has worked with various women’s reproductive health products encompassing a diversity of routes of administration (including topical and parenteral), drug delivery systems (short acting, long acting and combination drug-device products) and indications (including prevention of HIV/STIs, contraception, maternal and neonatal health, multipurpose prevention). She also has extensive experience in leading the preclinical evaluation of new vaginal drug products in various animal models, and developing IND-enabling nonclinical study testing plans for complex combination drug-device products. Dr. Clark received her B.S. in Neurobiology, Physiology and Behavior from the University of California, Davis in 2001 and her Ph.D. in Bioengineering from the University of Utah in 2008.  Her research interests are in conducting preclinical proof-of-concept studies of innovative and promising women’s/global health technologies and potential solutions to some of the world’s greatest unmet needs, and enabling their translational development from preclinical through clinical stages of development.


Douglas Colvard

Douglas Colvard, Ph.D.

Deputy Director for Programs

Dr. Colvard brings to CONRAD his expertise as the Assistant Professor in Obstetrics and Gynecology at EVMS in the areas of male reproductive biology, immunocontraception and STI. . He received his B.A. degree in Chemistry in 1977 and his Ph.D. in Biochemistry in 1983 from the University of North Carolina (UNC) at Chapel Hill. In 1986, he completed his postdoctoral fellowship at the UNC School of Medicine, where he studied the mechanisms of action of androgens and male fertility. From 1986 until he joined CONRAD in 1989, Dr. Colvard served as co-director of the Biopsy Nuclear Binding Laboratory at the Mayo Clinic in Rochester, Minnesota. He was the CONRAD team lead for a multi-center male hormonal contraceptive efficacy study co-sponsored by WHO.


Tim McCormick

Tim McCormick, Ph.D.

Director, CMC

Dr. McCormick has a Ph.D. in Analytical Chemistry from Villanova University and extensive experience in the pharmaceutical industry. He has expertise in analytical method development and validation for both drug substance and drug product and has worked for various organizations including Wyeth Laboratories and DuPont Merck Pharmaceuticals. He has also been involved in microbicide product development starting with Biosyn, Inc. in 2003 and moving to CONRAD in 2006 where he has overseen and coordinated various aspects of product development such as: preformulation, formulation development, analytical/bioanalytical method development/validation, preclinical toxicology and pharmacokinetic studies, stability studies, and process development and manufacturing of drug substance and clinical trial materials. Dr. McCormick is thoroughly familiar with industry regulations and GMPs, and has written the CMC sections of regulatory filings. He also oversees the Quality Assurance function within CONRAD.


Jill Schwartz

Jill Schwartz, M.D.

Director, Medical

Dr. Schwartz is the Medical Director for CONRAD and holds the position of Professor of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS). Dr. Schwartz received her medical degree from Mount Sinai School of Medicine and completed a residency in Obstetrics and Gynecology at George Washington University Medical Center. She completed a fellowship in contraceptive research and family planning at University of Pittsburgh Medical Center and served on the faculty prior to coming to CONRAD/EVMS. As an expert in the field of women’s health, Dr. Schwartz has been involved in numerous clinical trials testing spermicides, systemic hormonal contraceptives and slippage and breakage studies of barrier devices, and has led a multicenter contraceptive study of a new one-size diaphragm currently distributed in the US as Caya®.  In addition, she has been on the leadership team for pivotal HIV prevention trials and has contributed to CONRAD’s state of the art research in the assessment of microbicides, including pharmacokinetic and pharmacodynamics testing of antiretroviral microbicides in clinical trials.  Dr. Schwartz serves on numerous safety and advisory committees and has published extensively in the Contraceptive and HIV Prevention field.


Andrea Thurman

Andrea Thurman, M.D.

Director of the Clinical Research Ctr / Professor of Obstetrics and Gynecology

Dr. Thurman is the Director of the Clinical Research Center at EVMS.  She is the site Principal Investigator for CONRAD Clinical Trials and is a Principal Investigator on several commercially funded studies related to women’s reproductive health.  She is an investigator for the NICHD Clinical Contraceptive Trials Network.  She works closely with the CONRAD laboratory on clinical and pre-clinical projects, including statistical analyses and data management.  She served as the technical leader for CONRAD cooperative agreements focusing on adherence to HIV PrEP and incorporating human centered design to increase uptake and adherence to PrEP by young women in South Africa.  She is the project lead and site PI for an NICHD grant examining mucosal immunity in premenopausal and postmenopausal women.  With over 9 years of experience at CONRAD, she has worked on dozens of CONRAD clinical projects focusing on different dosage forms for both oral and topical PrEP,  multi-purpose prevention technologies and the interaction between exogenous contraceptives and reproductive tract infections on mucosal susceptibility to HIV.  Dr. Thurman received her B.A. (summa cum laude) in Chemistry and Studio Art from Kenyon College in 1990.  She received her MD from the University of Chicago Pritzker School of Medicine in 1994 and did her Obstetrics and Gynecology training at Bethesda Naval Hospital.  She was previously a staff physician at US Naval Hospital Yokosuka Japan and was on faculty at the Medical University of South Carolina and the University of Texas Health Sciences Center San Antonio.


Onkar N. Singh

Onkar N. Singh, PhD, M.B.A.


Dr. Singh joined CONRAD/EVMS as Director, Pharmaceutical Development in April 2017. To CONRAD, Dr. Singh brings over twenty-five years of pharmaceutical products development experience, mostly gained in a position of increasing responsibility at Alcon Laboratories (now Novartis) from 1995 to 2015. Before joining CONRAD, Dr. Singh was Director of Product Development at Insys Therapeutics. Dr. Singh has experience in successfully developing wide ranges of dosage forms for small molecules and biologics. Several of his identified formulations during his tenure at Alcon have resulted in commercial products. Dr. Singh received his B.Pharm. (1982), M.Pharm. (1984) from IIT, BHU, India; Ph.D. in Pharmaceutics from the University of Illinois at Chicago (1992) and his M.B.A. from University of Texas at Arlington (2004). Dr. Singh is holder of more than sixty issued patents worldwide. Dr. Singh has co-edited a book entitled “Pharmaceutical Suspensions: From Formulation Development to Manufacturing” and is an editorial board member of American Pharmaceutical Review journal.  At CONRAD, Dr. Singh is responsible for the development of stable, safe and effective pharmaceutical products of diverse drug delivery systems such as immediate release, long acting and multipurpose technologies for prevention of HIV/STIs, contraception, maternal and neonatal health.

Julie B. Standley

Julie B. Standley, CPA, CGMA

Director of Finance

Julie has served as Director of Finance of CONRAD at EVMS since 2009.  She has prior experience working in diverse industries,  both for-profit and non-profit, and is knowledgeable  in GAAP as well as grants financial reporting, auditing and compliance, both federal and private; stakeholder and program  management; funding  opportunities to support scientific research in global health; strategic planning; developing budget proposals and justifications; negotiating funding opportunities to support  scientific research related to women's health, contributing to gender empowerment and equality. She joined EVMS as the Controller to oversee general accounting, including accounts payable, payroll, cash receipts and billing. Earlier in her career, she worked as an auditor for PricewaterhouseCoopers LLP. She has a Bachelor of Science in Business Administration in Accounting from Auburn University and is a licensed CPA in the Commonwealth of Virginia. She has 20+ years of experience in forecasting, budgeting, financial reporting and analysis and auditing.